News Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Market Closed - Euronext Bruxelles Other stock markets 09:07:36 26/04/2024 pm IST			5-day change	1st Jan Change
11.7 ^EUR	-1.27%		-.--%	-8.24%

14/03	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
14/03	Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	14/03	CI
Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024	14/03
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook	14/03	GL
Communication at the request of the FSMA on the transactions with Qliniq	14/03	GL
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Communication at the request of the FSMA on the transactions with Qliniq	14/03	AQ
Hyloris to Report 2023 Full-Year Results on 14 March 2024	08/03	GL
Hyloris to Report 2023 Full-Year Results on 14 March 2024	08/03	AQ
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada	28/02	MT
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada	27/02	GL
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse	15/02	MT
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	14/02	GL
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	14/02	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	07/02	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	06/02	MT
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)	30/01	GL
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis	30/01	CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	19/01	MT
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)	18/01	GL
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus	18/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Summary

Filters